Moreover, a recent study examined CD1d levels in anaplastic thyroid carcinomas and observed significantly higher levels of CD1d, compared to normal thyroid tissue [75], implicating a potential role for NKT cell-based therapy in this disease as well. This evidence concerns the gene CD1D and thyroid gland undifferentiated (anaplastic) carcinoma.